Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.2.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Apr. 30, 2024
Apr. 30, 2023
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses:    
Research and development costs 407,431 468,536
Compensation expense 1,322,414 1,234,956
Director fees 1,141,215 951,347
Legal and professional 1,531,626 2,687,978
Intangible asset impairment 2,000,000 0
General and administrative 2,117,322 1,112,677
Total operating expenses 8,520,008 6,455,494
Loss from operations (8,520,008) (6,455,494)
Other income (expense):    
Interest income 3,398,819 1,937,499
Change in fair value of warrant liability 3,343,000 0
Change in fair value of derivative liability 586,000 0
Change in fair value of convertible note receivable 1,089,000 0
Change in fair value of warrant asset 1,818,000 0
Loss on long term asset (1,572,193) 0
Other income, net 191,145 202,002
Total other income, net 8,853,771 2,139,501
Net income (loss) 333,763 (4,315,993)
Preferred stock dividends (2,517,645) 0
Preferred stock accretion (15,053,521) 0
Net loss attributable to common stockholders $ (17,237,403) $ (4,315,993)
Basic loss per share attributable to common stockholders $ (1.80) $ (0.22)
Diluted loss per share attributable to common stockholders $ (1.80) $ (0.22)
Weighted average shares outstanding basic 9,581,059 19,489,204
Weighted average shares outstanding diluted 9,581,059 19,489,204